"In light of the promising Knee Osteoarthritis Phase IIa six month follow-up results we decided to explore the efficacy of our proprietary ReJoinTM therapy on an additional orthopedic indication, Cartilage Defects (CD)," said Dr. William (Wei) Cao, Chief Executive Officer of the Company. "We are thankful for the approval by the ethics committee of Shanghai Ninth People’s Hospital for this exploratory clinical research, and very much look forward to finding the promise of ReJoinTM therapy on CD. The repair of CD would greatly improve the quality of life for CD patients, allowing for greater mobility, flexibility and less pain."
About the Study
The clinical study is a single-blind, randomly assigned, controlled clinical research study that will enroll thirty patients with the purpose of evaluating the safety and efficacy of haMPCs combined with lavage, debridement, and/or microfracture under arthroscopy treatment for cartilage defects. In addition, this study shall serve as a supporting study of ReJoinTM for the treatment of Knee Osteoarthritis (KOA) so as to bring additional clinical data to the protocol of future KOA trials.
The study will be conducted by Shanghai Ninth People’s Hospital, a leading teaching hospital affiliated with Shanghai Jiao Tong University School of Medicine. Professor Wang You, Director of the hospital’s orthopedics department and Vice Chairperson of the Chinese Knee Society, will lead the study as Principal Investigator.